Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
252.96
-5.96 (-2.30%)
At close: Oct 23, 2026, 4:00 PM EDT
253.60
+0.64 (0.25%)
After-hours: Oct 23, 2026, 4:12 PM EDT
PRAX Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
168
Market Cap
7.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 8.55M | 6.11M | 249.53% |
| Dec 31, 2023 | 2.45M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ionis Pharmaceuticals | 874.09M |
| TG Therapeutics | 799.54M |
| Axsome Therapeutics | 776.57M |
| Arrowhead Pharmaceuticals | 669.50M |
| Iovance Biotherapeutics | 324.97M |
| Ligand Pharmaceuticals | 290.54M |
| Rhythm Pharmaceuticals | 239.92M |
| Cytokinetics | 67.67M |
PRAX News
- 2 days ago - 3 ‘Strong Buy’ High-Risk Stocks with Double-Gain Potential - TipRanks
- 8 days ago - Praxis Precision initiated with an Overweight at JPMorgan - TheFly
- 8 days ago - Praxis Precision initiated with a Buy at UBS - TheFly
- 17 days ago - Praxis Precision price target raised to $826 from $810 at BTIG - TheFly
- 21 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Praxis Precision price target raised to $575 from $470 at Goldman Sachs - TheFly
- 2 months ago - Praxis Precision price target raised to $945 from $765 at Raymond James - TheFly
- 2 months ago - Praxis Precision price target raised to $462 from $449 at RBC Capital - TheFly